Asia Pacific Erythropoietin Drugs Market By Product ( Epoetin-alpha, Epoetin-beta, Darbepoetin-alfa And Others) , By Application ( Cancer, Haematology, Renal Diseases And Neurology) , By Drug Class ( Biologics And Biosimilar) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts(2017–2022)
Asia Pacific Erythropoietin Drugs Market By Product ( Epoetin-alpha, Epoetin-beta, Darbepoetin-alfa And Others) , By Application ( Cancer, Haematology, Renal Diseases And Neurology) , By Drug Class ( Biologics And Biosimilar) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts(2017–2022)
ID: 6775 | Pages: 145 | March 2018 | Region: Asia Pacific
Asia Pacific Erythropoietin Drugs Market was worth USD 1.81 billion in 2017 and estimated to be growing at a CAGR of 9.87%, to reach USD 2.9 billion by 2022. Erythropoietin is present in the bone marrow cells controlling the production of red blood cells. They can be used for the treatment of anaemia, HIV and Cancer. Various synthetic forms of erythropoietin are available in the market due to advancements in recombinant DNA technology.
Increased incidence of anaemia, rising commercialisation of EPO drugs and favourable reimbursement policies are further driving the market growth. As cheaper biosimilars are also available the market is expected to propel during the forecast period.
The market for Erythropoietin Drugs is broadly categorized into product, application and drug class. By product the market is divided into Epoetin-alpha, epoetin-beta, darbepoetin-alfa and others. Epoietin-alfa holds the largest market share. By application the market is classified into cancer, haematology, renal diseases and neurology. Cancer segment is predicted to be fastest growing segment. By drug class the market is segmented into biologics and biosimilar. Biosimilars are predicted to grow at a significant rate during the forecast period. On the basis of geography, the market is analysed under various regions namely China, India, Japan, Australia and South Korea. Asia Pacific is expected to grow at a high CAGR.
Some of the major companies dominating the market, by their products and services include Johnson & Johnson, Celltrion, Inc, Teva Pharmaceutical Industries Ltd. , Sun Pharmaceutical Industries Ltd. , Dr. Reddy’s Laboratories Ltd.Amgen, Inc. , F. Hoffmann-La Roche Ltd. , LG Life Sciences Ltd. , Biocon Limited and Intas Pharmaceuticals Ltd.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Epoetin-alfa
5.1.3 Epoetin-beta
5.1.4 Darbepoetin-alfa
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Application
5.2.1 Introduction
5.2.2 Cancer
5.2.3 Hematology
5.2.4 Renal diseases
5.2.5 Y-o-Y Growth Analysis, By application
5.2.6 Market Attractiveness Analysis, By application
5.2.7 Market Share Analysis, By application
5.3 Drug class
5.3.1 Introduction
5.3.2 Biologics
5.3.3 Biosimilars
5.3.4 Y-o-Y Growth Analysis, By drug class
5.3.5 Market Attractiveness Analysis, By drug class
5.3.6 Market Share Analysis, By drug class
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By application
6.1.3.4 By drug class
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By application
6.1.4.4 By drug class
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By application
6.1.5.4 By drug class
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Johnson & Johnson
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Celltrion, Inc.
8.3 Teva Pharmaceutical Industries Ltd.
8.4 Amgen, Inc.
8.5 F. Hoffmann-La Roche Ltd.
8.6 LG Life Sciences Ltd.
8.7 Biocon Limited
8.8 Intas Pharmaceuticals Ltd.
8.9 Sun Pharmaceutical Industries Ltd.
8.10 Dr. Reddy’s Laboratories Ltd.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
- Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
- Segment-level analysis in terms of Product, by Application along with market size forecasts and estimations to detect key areas of industry growth in detail
- Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
- Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
- Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
- A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
- Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
- An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
- Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
| Title | Price | Add To Cart |
- Asia Pacific Erythropoeitin Drugs Market By Product, From 2016-2022 ( USD Billion )
- Asia Pacific Epoetin-alfa Market By Region, From 2016-2022 ( USD Billion )
- Asia Pacific Epoetin-beta Market By Region, From 2016-2022 ( USD Billion )
- Asia Pacific Darbepoetin-alfa Market By Region, From 2016-2022 ( USD Billion )
- Asia Pacific Erythropoeitin Drugs Market By Application, From 2016-2022 ( USD Billion )
- Asia Pacific Cancer Market By Region, From 2016-2022 ( USD Billion )
- Asia Pacific Hematology Market By Region, From 2016-2022 ( USD Billion )
- Asia Pacific Renal diseases Market By Region, From 2016-2022 ( USD Billion )
- Asia Pacific Neurology Market By Region, From 2016-2022 ( USD Billion )
- Asia Pacific Erythropoeitin Drugs Market By Drug class, From 2016-2022 ( USD Billion )
- Asia Pacific Biologics Market By Region, From 2016-2022 ( USD Billion )
- Asia Pacific Biosimilars Market By Region, From 2016-2022 ( USD Billion )
- Japan Erythropoeitin Drugs Market By Product, From 2016-2022 ( USD Billion )
- Japan Erythropoeitin Drugs Market By Application, From 2016-2022 ( USD Billion )
- Japan Erythropoeitin Drugs Market By Drug class, From 2016-2022 ( USD Billion )
- China Erythropoeitin Drugs Market By Product, From 2016-2022 ( USD Billion )
- China Erythropoeitin Drugs Market By Application, From 2016-2022 ( USD Billion )
- China Erythropoeitin Drugs Market By Drug class, From 2016-2022 ( USD Billion )
- India Erythropoeitin Drugs Market By Product, From 2016-2022 ( USD Billion )
- India Erythropoeitin Drugs Market By Application, From 2016-2022 ( USD Billion )
- India Erythropoeitin Drugs Market By Drug class, From 2016-2022 ( USD Billion )
- Australia Erythropoeitin Drugs Market By Product, From 2016-2022 ( USD Billion )
- Australia Erythropoeitin Drugs Market By Application, From 2016-2022 ( USD Billion )
- Australia Erythropoeitin Drugs Market By Drug class, From 2016-2022 ( USD Billion )
- South Korea Erythropoeitin Drugs Market By Product, From 2016-2022 ( USD Billion )
- South Korea Erythropoeitin Drugs Market By Application, From 2016-2022 ( USD Billion )
- South Korea Erythropoeitin Drugs Market By Drug class, From 2016-2022 ( USD Billion )
Licence Type 
Clients
Why buy reports from Market Data Forecast
Free Customization
Free report customization that helps you gain required information for always being one step ahead of the competition
Post Purchase Support
6 months of post purchase support via email and phone; serving your needs 24x7 and helping you troubleshoot any technical issues
Best Price guaranteed
Customer focused research services and expertly devised strategic analyses made into premium quality reports at lowest prices
Insightful Snapshots
Summarized overviews of entire reports into customized presentations to ascertain market estimations and driving forces at a quick glance